Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels.
暂无分享,去创建一个
Kimberly Walter | Noriyuki Omura | Margaret Griffith | Michael Goggins | Seung-Mo Hong | Ang Li | Seung‐Mo Hong | K. Walter | M. Goggins | Ang Li | N. Omura | A. Vincent | M. Griffith | Michael Borges | Audrey Vincent | Michael Borges | Audrey Vincent
[1] M. Klymkowsky,et al. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. , 2009, The American journal of pathology.
[2] R. Hawes,et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. , 2009, Gastrointestinal endoscopy.
[3] E. Ng,et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.
[4] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[5] M. F. Shannon,et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.
[6] Michael Goggins,et al. Update on pancreatic intraepithelial neoplasia. , 2008, International journal of clinical and experimental pathology.
[7] Sun-Mi Park,et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.
[8] S. Baylin,et al. Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer , 2008, Clinical Cancer Research.
[9] T. Brabletz,et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.
[10] R H Hruban,et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.
[11] Seung‐Mo Hong,et al. Pancreatic cancer associated fibroblasts display normal allelotypes , 2008, Cancer biology & therapy.
[12] M. Goggins,et al. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] Seung‐Mo Hong,et al. Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[14] Seung‐Mo Hong,et al. Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts , 2010, Clinical Cancer Research.
[15] F. Lyko,et al. Methylation of Human MicroRNA Genes in Normal and Neoplastic Cells , 2007, Cell cycle.
[16] Michael Goggins,et al. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. , 2006, Gastroenterology.
[17] R. Hruban,et al. Familial pancreatic cancer. , 2009, Archives of pathology & laboratory medicine.
[18] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[19] C. Iacobuzio-Donahue,et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.
[20] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[21] D. Saur,et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.
[22] Peter A. Jones,et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.
[23] M. Goggins,et al. Epigenetics and epigenetic alterations in pancreatic cancer. , 2009, International journal of clinical and experimental pathology.
[24] M M Grajower,et al. Familial pancreatic cancer. , 1983, Annals of internal medicine.
[25] S. Yachida,et al. Genetic and Epigenetic Alterations of Familial Pancreatic Cancers , 2008, Cancer Epidemiology Biomarkers & Prevention.
[26] I. Haviv,et al. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. , 2009, Cancer research.
[27] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[28] A. Jimeno,et al. Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma , 2008, Cancer biology & therapy.
[29] A. Postigo,et al. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins , 2003, The EMBO journal.
[30] R. Hruban,et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection , 2008, Cancer biology & therapy.
[31] N. Miller,et al. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer , 2008, BMC Molecular Biology.
[32] R. Hruban,et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. , 2006, Cancer research.
[33] C. Iacobuzio-Donahue,et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Alison P. Klein,et al. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.
[35] J. Alsina,et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. , 2010, Gastroenterology.
[36] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[37] M. Fraga,et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. , 2007, Cancer research.
[38] M. Goggins,et al. Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.
[39] Woonyoung Choi,et al. miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy , 2009, Clinical Cancer Research.
[40] Jae Hoon Kim,et al. MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.
[41] J. Cameron,et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. , 2003, Cancer research.
[42] Ann M. Killary,et al. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease , 2009, Cancer Prevention Research.
[43] Jun Yu,et al. 1070 Differential Expression of MicroRNAs in Plasma of Colorectal Cancer Patients: A Potential Marker for Colorectal Cancer Screening , 2009 .
[44] M. Korpal,et al. The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.
[45] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[46] Zhiwei Wang,et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. , 2009, Cancer research.
[47] T. Gress,et al. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer , 2007, Oncogene.
[48] J. Nesland,et al. Snail, Slug, and Smad‐interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma , 2005, Cancer.
[49] E. Fishman,et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[50] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[51] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[52] Huamin Wang,et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.
[53] Zhiwei Wang,et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.
[54] A. Harris,et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.